Nucleocytoplasmic transport articles
- 4-Octyl itaconate reduces influenza A replication by targeting the nuclear export protein CRM1.
Ribó-Molina P, Weiss HJ, Susma B, van Nieuwkoop S, Persoons L, Zheng Y, Ruzek M, Daelemans D, Fouchier RAM, O’Neill LAJ, van den Hoogen BG.
J Virol. 2023 Oct 31. 97(10):e0132523. doi: 10.1128/jvi.01325-23.
- E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of XPO1.
Kwanten B, Deconick T, Walker C, Wang F, Landesman Y, Daelemans D. Biomed Pharmacother. 2023 Apr. 160:114305. doi: 10.1016/j.biopha.2023.114305.
- Cellular Stress Induces Nucleocytoplasmic Transport Deficits Independent of Stress Granules.
Vanneste J, Vercruysse T, Boeynaems S, Van Damme P, Daelemans D, Van Den Bosch L. Biomedicines. 2022 May 3. 10(5):1057. doi: 10.3390/biomedicines10051057.
- Inhibition of XPO-1 Mediated Nuclear Export through the Michael-Acceptor Character of Chalcones.
Gargantilla M, López-Fernández J, Camarasa MJ, Persoons L, Daelemans D, Priego EM, Pérez-Pérez MJ. Pharmaceuticals (Basel). 2021 Nov 6. 14(11):1131. doi: 10.3390/ph14111131.
- The material properties of a bacterial-derived biomolecular condensate tune biological function in natural and synthetic systems.
Lasker K, Boeynaems S, Lam V, Scholl D, Stainton E, Briner A, Jacquemyn M, Daelemans D, Deniz A, Villa E, Holehouse AS, Gitler AD, Shapiro L.
Nat Commun. 2022 Sep 26. 13(1):5643. doi: 10.1038/s41467-022-33221-z.
- Cellular Stress Induces Nucleocytoplasmic Transport Deficits Independent of Stress Granules.
Vanneste J, Vercruysse T, Boeynaems S, Van Damme P, Daelemans D, Van Den Bosch L. Biomedicines. 2022 May 3. 10(5):1057. doi: 10.3390/biomedicines10051057.
- Genome-wide CRISPR screening identifies TMEM106B as a proviral host factor for SARS-CoV-2.
Baggen J, Persoons L, Vanstreels E, Jansen S, Van Looveren D, Boeckx B, Geudens V, De Man J, Jochmans D, Wauters J, Wauters E, Vanaudenaerde BM, Lambrechts D, Neyts J, Dallmeier K, Thibaut HJ, Jacquemyn M, Maes P, Daelemans D. Nat Genet. 2021 doi: 10.1038/s41588-021-00805-2
- Intermedilysin cytolytic activity depends on heparan sulfates and membrane composition.
Drabavicius G, Daelemans D. PLoS Genet. 2021 doi: 10.1371/journal.pgen.1009387.
- enAsCas12a Enables CRISPR-Directed Evolution to Screen for Functional Drug Resistance Mutations in Sequences Inaccessible to SpCas9.
Neggers JE, Jacquemyn M, Dierckx T, Kleinstiver BP, Thibaut HJ, Daelemans D. Mol Ther. 2021 doi: 10.1016/j.ymthe.2020.09.025
- Quantitative Nucelocytoplasmic Transport Assays in Cellular Models of Neurodegeneration
Vanneste J, Vercruysse T, Van Damme P, Van Den Bosch L, Daelemans D. Bio Protoc. 2020 Jun 20;10(12):e3659. doi: 10.21769/BioProtoc.3659.
- Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma.
Azmi AS, Khan HY, Muqbil I, Aboukameel A, Neggers JE, Daelemans D, Mahipal A, Dyson G, Kamgar M, Al-Hallak MN, Tesfaye A, Kim S, Shidham V, M Mohammad R, Philip PA. Clin Cancer Res. 2020 Mar 15. 26(6):1338-1348. doi: 10.1158/1078-0432.CCR-19-1728.
- ATXN1 repeat expansions confer risk for amyotrophic lateral sclerosis and contribute to TDP-43 mislocalization.
Tazelaar GHP, Boeynaems S, De Decker M, van Vugt JJFA, Kool L, Goedee HS, McLaughlin RL, Sproviero W, Iacoangeli A, Moisse M, Jacquemyn M, Daelemans D, Dekker AM, van der Spek RA, Westeneng HJ, Kenna KP, Assialioui A, Da Silva N; Project MinE ALS Sequencing Consortium; Povedano M, Pardina JSM, Hardiman O, Salachas F, Millecamps S, Vourc’h P, Corcia P, Couratier P, Morrison KE, Shaw PJ, Shaw CE, Pasterkamp RJ, Landers JE, Van Den Bosch L, Robberecht W, Al-Chalabi A, van den Berg LH, Van Damme P, Veldink JH, van Es MA. Brain Commun. 2020 May 19;2(2):fcaa064. doi: 10.1093/braincomms/fcaa064.
- STK38 kinase acts as XPO1 gatekeeper regulating the nuclear export of autophagy proteins and other cargoes.
Martin AP, Jacquemyn M, Lipecka J, Chhuon C, Aushev VN, Meunier B, Singh MK, Carpi N, Piel M, Codogno P, Hergovich A, Parrini MC, Zalcman G, Guerrera IC, Daelemans D, Camonis JH. EMBO Rep. 2019 Nov 5. 20(11):e48150. doi: 10.15252/embr.201948150.
- C9orf72-generated poly-GR and poly-PR do not directly interfere with nucleocytoplasmic transport.
Vanneste J, Vercruysse T, Boeynaems S, Sicart A, Van Damme P, Daelemans D, Van Den Bosch L. Sci Rep. 2019 Oct 31. 9(1):15728. doi: 10.1038/s41598-019-52035-6.
- Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes.
Neggers JE, Kwanten B, Dierckx T, Noguchi H, Voet A, Bral L, Minner K, Massant B, Kint N, Delforge M, Vercruysse T, Baloglu E, Senapedis W, Jacquemyn M, Daelemans D. Nat Comm. 2018.
- The second-generation exportin-1 inhibitor KPT-8602 demonstrates potent activity against acute lymphoblastic leukemia.
Vercruysse T, De Bie J, Neggers J, Jacquemyn M, Vanstreels E, Schmid-Burgk JL, Hornung V, Baloglu E, Landesman Y, Senapedis W, Shacham S, Dagklis A, Cools J, Daelemans D. Clin Cancer Res. 2016 Oct 25.
- XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
Kim J, McMillan E, Kim HS, Venkateswaran N, Makkar G, Rodriguez-Canales J, Villalobos P, Neggers JE, Mendiratta S, Wei S, Landesman Y, Senapedis W, Baloglu E, Chow CB, Frink RE, Gao B, Roth M, Minna JD, Daelemans D, Wistuba II, Posner BA, Scaglioni PP, White MA. Nature. 2016 Oct 6;538(7623):114-117
- Human exportin-1 is a target for combined therapy of HIV and AIDS related lymphoma.
Boons E, Vanstreels E, Jacquemyn M, Nogueira TC, Neggers JE, Vercruysse T, van den Oord J, Tamir S, Shacahm S, Landesman Y, Snoeck R, Pannecouque C, Andrei G, Daelemans D. EBioMedicine. 2015 2:1102-1113
- Identifying Drug-Target Selectivity of Small-Molecule CRM1/XPO1 Inhibitors by CRISPR/Cas9 Genome Editing.
Neggers JE, Vercruysse T, Jacquemyn M, Vanstreels E, Baloglu E, Shacham S, Crochiere M, Landesman Y, Daelemans D.
Chem Biol. 2015 Jan 8. pii: S1074-5521(14)00425-6
- Quantitative Nucleocytoplasmic Transport Assays in Cellular Models of Neurodegeneration.
Vanneste J, Vercruysse T, Van Damme P, Van Den Bosch L, Daelemans D. Bio Protoc. 2020 Jun 20. 10(12):e3659. doi: 10.21769/BioProtoc.3659.
- XPO1 inhibitors represent a novel therapeutic option in Adult T-cell Leukemia, triggering p53-mediated caspase-dependent apoptosis.
Boons E, Nogueira TC, Dierckx T, Menezes SM, Jacquemyn M, Tamir S, Landesman Y, Farré L, Bittencourt A, Kataoka K, Ogawa S, Snoeck R, Andrei G, Van Weyenbergh J, Daelemans D. Blood Cancer J. 2021 doi: 10.1038/s41408-021-00409-3.
- Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma.
Azmi AS, Khan HY, Muqbil I, Aboukameel A, Neggers JE, Daelemans D, Mahipal A, Dyson G, Kamgar M, Al-Hallak MN, Tesfaye A, Kim S, Shidham V, M Mohammad R, Philip PA. Clin Cancer Res. 2020 Mar 15. 26(6):1338-1348. doi: 10.1158/1078-0432.CCR-19-1728. $
- C9orf72-generated poly-GR and poly-PR do not directly interfere with nucleocytoplasmic transport.
Vanneste J, Vercruysse T, Boeynaems S, Sicart A, Van Damme P, Daelemans D, Van Den Bosch L. Sci Rep. 2019 Oct 31. 9(1):15728. doi: 10.1038/s41598-019-52035-6.
- STK38 kinase acts as XPO1 gatekeeper regulating the nuclear export of autophagy proteins and other cargoes.
Martin AP, Jacquemyn M, Lipecka J, Chhuon C, Aushev VN, Meunier B, Singh MK, Carpi N, Piel M, Codogno P, Hergovich A, Parrini MC, Zalcman G, Guerrera IC, Daelemans D, Camonis JH. EMBO Rep. 2019 Nov 5. 20(11):e48150. doi: 10.15252/embr.201948150.
- Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression.
Aboukameel A, Muqbil I, Baloglu E, Senapedis W, Landesman Y, Argueta C, Kauffman M, Chang H, Kashyap T, Shacham S, Neggers JE, Daelemans D, Heath EI, Azmi AS. Oncotarget. 2018 Oct 19. 9(82):35327-35342. doi: 10.18632/oncotarget.26239.
- Targeting the XPO1-dependent nuclear export of E2F7 reverses anthracycline resistance in head and neck squamous cell carcinomas.
Saenz-Ponce N, Pillay R, de Long LM, Kashyap T, Argueta C, Landesman Y, Hazar-Rethinam M, Boros S, Panizza B, Jacquemyn M, Daelemans D, Gannon OM, Saunders NA.
Sci Transl Med. 2018 Jun 27. 10(447):eaar7223. doi: 10.1126/scitranslmed.aar7223.
- The second-generation exportin-1 inhibitor KPT-8602 demonstrates potent activity against acute lymphoblastic leukemia.
Vercruysse T, De Bie J, Neggers J, Jacquemyn M, Vanstreels E, Schmid-Burgk JL, Hornung V, Baloglu E, Landesman Y, Senapedis W, Shacham S, Dagklis A, Cools J, Daelemans D. Clin Cancer Res. 2016 Oct 25.
- XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
Kim J, McMillan E, Kim HS, Venkateswaran N, Makkar G, Rodriguez-Canales J, Villalobos P, Neggers JE, Mendiratta S, Wei S, Landesman Y, Senapedis W, Baloglu E, Chow CB, Frink RE, Gao B, Roth M, Minna JD, Daelemans D, Wistuba II, Posner BA, Scaglioni PP, White MA. Nature. 2016 Oct 6;538(7623):114-117
- Heterozygous mutation of cysteine528 in XPO1 is sufficient for resistance to selective inhibitors of nuclear export.
Neggers JE, Vanstreels E, Baloglu E, Shacham S, Landesman Y, Daelemans D. Oncotarget. 2016 Oct 18;7(42):68842-68850.
- Human exportin-1 is a target for combined therapy of HIV and AIDS related lymphoma.
Boons E, Vanstreels E, Jacquemyn M, Nogueira TC, Neggers JE, Vercruysse T, van den Oord J, Tamir S, Shacahm S, Landesman Y, Snoeck R, Pannecouque C, Andrei G, Daelemans D. EBioMedicine. 2015 2:1102-1113
- Identifying Drug-Target Selectivity of Small-Molecule CRM1/XPO1 Inhibitors by CRISPR/Cas9 Genome Editing.
Neggers JE, Vercruysse T, Jacquemyn M, Vanstreels E, Baloglu E, Shacham S, Crochiere M, Landesman Y, Daelemans D. Chem Biol. 2015 Jan 8. pii: S1074-5521(14)00425-6.
- Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia.
Lapalombella R, Sun Q, Williams K, Tangeman L, Jha S, Zhong Y, Goettl V, Mahoney E, Berglund C, Gupta S, Farmer A, Mani R, Johnson AJ, Lucas D, Mo X, Daelemans D, Sandanayaka V, Shechter S, McCauley D, Shacham S, Kauffman M, Chook YM, Byrd JC. Blood. 2012 Nov 29;120(23):4621-34.
- Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: structure-activity relationship and mechanism of action.
Van Neck T, Pannecouque C, Vanstreels E, Stevens M, Dehaen W, Daelemans D. Bioorg Med Chem. 2008 Nov 1;16(21):9487-97.
- Kinetic and molecular analysis of nuclear export factor CRM1 association with its cargo in vivo.
Daelemans D, Costes SV, Lockett S, Pavlakis GN. Mol Cell Biol. 2005 Jan;25(2):728-39.
- A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export.
Daelemans D, Afonina E, Nilsson J, Werner G, Kjems J, De Clercq E, Pavlakis GN, Vandamme AM. Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14440-5.